Abstract
The structural studies on two bromo-substituted derivatives of 2-deoxy-d-glucose (2-DG), namely 2-deoxy-2-bromo-d-glucose (2-BG) and 2-deoxy-2-bromo-d-mannose (2-BM) are described. 2-DG itself is an inhibitor of hexokinase, the first enzyme in the glycolysis process, playing a vital role in both cancer cell metabolism and viral replication in host cells. Because of that, 2-DG derivatives are considered as potential anti-cancer and anti-viral drugs. An X-ray quantum crystallography approach allowed us to obtain more accurate positions of hydrogen atoms by applying Hirshfeld atom refinement, providing a better description of hydrogen bonding even in the case of data from routine X-ray experiments. Obtained structures showed that the introduction of bromine at the C2 position in the pyranose ring has a minor influence on its conformation but still, it has a noticeable effect on the crystal structure. Bromine imposes the formation of a layered supramolecular landscape containing hydrogen bonds, which involves the bromine atom. Periodic DFT calculations of cohesive and interaction energies (at the B3LYP level of theory) have supported these findings and highlighted energetic changes upon bromine substitution. Based on molecular wavefunction from the refinement, we calculated the electrostatic potential, Laplacian, and ELI-D, and applied them to charge-density studies, which confirmed the geometry of hydrogen bonding and involvement of the bromine atom with these intermolecular interactions. NMR studies in the solution show that both compounds do not display significant differences in their anomeric equilibria compared to 2-DG, and the pyranose ring puckering is similar in both aqueous and solid state.
Original language | English |
---|---|
Pages (from-to) | 8345-8360 |
Number of pages | 16 |
Journal | RSC Advances |
Volume | 12 |
Issue number | 14 |
DOIs | |
State | Published - Mar 15 2022 |
Externally published | Yes |
Funding
This work was supported by National Science Centre in Poland (grants no. UMO-2017/25/B/NZ3/00251 and UMO-2017/24/C/NZ1/00366). Grant no. UMO-2017/25/B/NZ3/00251 is carried out with cooperation of Professor Waldemar Priebe, MD Anderson Cancer Center, where new derivatives were synthesized. The research was carried out at the Biological and Chemical Research Centre, University of Warsaw, established within the project co-financed by European Union from the European Regional Development Fund under the Operational Pro-gramme Innovative Economy, 2007–2013. The X-ray diffraction data collection was accomplished at the Core Facility for Crystallographic and Biophysical research to support the development of medicinal products. The “Core Facility for Crystallographic and Biophysical research to support the development of medicinal products” project is carried out within the TEAM-TECH Core Facility programme of the Foundation for Polish Science co-financed by the European Union under the European Regional Development Fund. W. Priebe is an inventor on patents covering new derivatives of . He is Chair of SAB and a shareholder of Moleculin Biotech, Inc., CNS Pharmaceuticals, and WPD Pharmaceuticals. His research is in part supported by the sponsor research grant from Moleculin Biotech, Inc. and CNS Pharmaceuticals. I. Fokt and R. Zielinski are listed as inventors on patents covering new analogues of , are consultants of Moleculin Biotech, Inc., and are shareholders of Moleculin Biotech, Inc. and CNS Pharmaceuticals. M. Ziemniak is an expert in WPD Pharamceuticals. K. Wozniak has been involved as a consultant in WPD Pharmaceuticals. B. Pająk is CSO for WPD Pharmaceuticals. The other authors declare no conflict of interest.
Funders | Funder number |
---|---|
Moleculin Biotech, Inc. | |
Division of Computer and Network Systems | |
European Commission | |
Fundacja na rzecz Nauki Polskiej | |
Narodowe Centrum Nauki | UMO-2017/24/C/NZ1/00366, UMO-2017/25/B/NZ3/00251 |
European Regional Development Fund |